A Case Report on the Management of Combined Factor Infertility and Successful Pregnancy with Intracytoplasmic Sperm Injection and In Vitro Fertilization After Cyclofert-IVA® Pretreatment
Background: Infertility affects about 17% of people worldwide, with most cases attributed to female,
male, or combined factors. While assisted reproductive technologies, particularly in-vitro fertilization
(IVF) and intracytoplasmic sperm injection (ICSI), are widely used treatment options, adjunct
nutraceutical therapies such as Cyclofert-IVA® have emerged to support female reproductive health
and improve factors associated with infertility.
Case Summary: We report the case of a 26-year-old Libyan woman presenting with a 3-year history
of primary infertility and no identifiable female pathology. Her hormonal profile, pelvic imaging, and
tubal patency were all within normal limits, indicating unexplained female infertility. However, the
male partner was diagnosed with oligo-astheno-teratozoospermia. Given the combined factor infertility
diagnosis, the couple underwent in vitro fertilization with intracytoplasmic sperm injection, following
a one-month course of Cyclofert-IVA®, a combination of dehydroepiandrosterone, high dose coenzyme
Q10, L-methylfolate, vitamins E and D, Ginkgo biloba, and omega-3 for the female partner. Three
blastocysts were transferred, resulting in a confirmed intrauterine clinical pregnancy with positive fetal
cardiac activity at 7 weeks' gestation.
Conclusion: A one-month Cyclofert-IVA® pretreatment before IVF/ICSI may improve fertility outcomes
in couples with combined factor infertility. However, larger prospective trials are needed to confirm its
efficacy and establish its role in routine infertility clinical practice.
